Recovery & Tissue Repair Research
The angiogenesis and tissue-repair signaling behind our recovery research line.
How This Works
Recovery research in this category spans EPO-derived tissue protection (ARA-290), gastric-juice-derived and thymosin-derived tissue repair peptides (BPC-157, TB-500), melanocortin-fragment anti-inflammatory signaling (KPV), and broad neuropeptide signaling (VIP). This is also the category where the gap between preclinical popularity and human clinical evidence is most pronounced — BPC-157 and TB-500 in particular are widely discussed based almost entirely on animal and in-vitro data, a distinction worth understanding before drawing conclusions from either compound's research.
Compounds Behind This Category
ARA-290 (Cibinetide)
ARA-290 was engineered to reproduce a small structural motif of erythropoietin's tertiary fold — the helix B region — without activating the classical erythropoietin receptor homodimer, avoiding EPO's hematopoietic (red-cell-stimulating) effect. By engaging an EPOR/CD131 heterocomplex instead, it activates anti-inflammatory and cytoprotective signaling studied for neuronal and vascular tissue repair. A blinded, placebo-controlled human trial in patients with sarcoidosis-associated small nerve fiber damage reported improved neuropathic symptoms and increased corneal nerve fiber density after 28 days of dosing.
ExploreBPC-157
BPC-157 is a synthetic partial sequence derived from a peptide identified in human gastric juice. Preclinically, it accelerates healing of tendon, ligament, muscle, and gut tissue by promoting fibroblast and tenocyte migration, cell survival under oxidative stress, and new blood vessel formation. A 2025 systematic review screened 544 articles and found only 36 met inclusion criteria — 35 preclinical (animal) studies and exactly one small retrospective clinical case series. Published clinical safety data for BPC-157 remains absent; the evidence base is overwhelmingly animal and in-vitro.
ExploreKPV
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (residues 11-13). It is taken up into immune and intestinal epithelial cells via the PepT1 transporter, where nanomolar concentrations suppress NF-kB and MAP kinase-driven pro-inflammatory cytokine production — a mechanism shown to be independent of melanocortin receptors despite KPV's alpha-MSH lineage. It has been studied primarily in mouse models of inflammatory bowel disease; no published human clinical trial data was identified.
ExploreTB-500 (Thymosin Beta-4 Fragment)
The marketed "TB-500" is a 7-residue fragment of the 43-amino-acid protein Thymosin Beta-4, but nearly all of the mechanistic and efficacy literature — angiogenesis, wound healing, and myoblast chemotaxis — was conducted with the full-length protein, not the fragment; only one identified study characterizes the fragment itself, and it is an analytical detection method paper, not an efficacy or safety study. Full-length Thymosin Beta-4 is an intracellular actin-monomer-binding protein that promotes cell migration and angiogenesis, partly via VEGF induction. This same pro-angiogenic mechanism has a documented dark side: full-length Tβ4-overexpressing tumor cells produced significantly larger tumors and more metastases in an animal cancer model, a legitimate mechanistic safety consideration given TB-500 is marketed on the identical mechanism.
ExploreVIP (Vasoactive Intestinal Peptide)
VIP binds VPAC1 and VPAC2, class B G-protein-coupled receptors that classically activate adenylate cyclase and raise intracellular cAMP. Through this signaling it modulates neural, gastrointestinal, immune, endocrine, and circadian processes; in pancreatic beta cells, VPAC2 activation triggers cAMP/PKA-mediated closure of ATP-sensitive potassium channels and subsequent insulin secretion, and VIP has also been studied as an endogenous anti-inflammatory neuropeptide that helps maintain immune tolerance.
Explore